Holen Sie sich die Stockscreener-App
2.84
17.36%
0.42
Handel nachbörslich:
2.94
0.10
+3.52%
Schlusskurs vom Vortag:
$2.42
Offen:
$2.41
24-Stunden-Volumen:
6.90M
Relative Volume:
7.02
Marktkapitalisierung:
$205.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-292.19M
KGV:
-0.6256
EPS:
-4.54
Netto-Cashflow:
$-208.41M
1W Leistung:
+110.37%
1M Leistung:
+101.42%
6M Leistung:
+123.62%
1J Leistung:
+2.16%
1-Tages-Spanne:
$2.3725
$3.06
1-Wochen-Bereich:
$1.32
$3.06
52-Wochen-Spanne:
$1.01
$3.06
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Firmenname
Zentalis Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 263-4333
Adresse
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Vergleichen Sie ZNTL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
2.84 | 174.85M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-12 | Hochstufung | Wedbush | Underperform → Neutral |
| 2024-06-20 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-06-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | Herabstufung | Wedbush | Neutral → Underperform |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-11-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | Eingeleitet | Cowen | Outperform |
| 2022-04-06 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-01-20 | Eingeleitet | Wedbush | Outperform |
| 2020-09-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Guggenheim | Buy |
| 2020-04-28 | Eingeleitet | Jefferies | Buy |
| 2020-04-28 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Zentalis Pharmaceuticals Inc Aktie (ZNTL) Neueste Nachrichten
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutDip Buying & AI Enhanced Market Trend Forecasts - ulpravda.ru
Is Zentalis Pharmaceuticals Inc. stock a top pick in earnings seasonJuly 2025 Levels & Daily Profit Focused Stock Screening - ulpravda.ru
Why analysts remain bullish on Zentalis Pharmaceuticals Inc. stockOil Prices & Risk Managed Investment Strategies - ulpravda.ru
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners - Yahoo Finance
Zentalis Pharmaceuticals: Balancing DENALI Momentum and ASPENOVA Visibility Against Pivotal Data and Execution Risk (Hold Rating Maintained) - TipRanks
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Zentalis Eyes A Pivotal 2026 As Azenosertib Advances Toward Potential Accelerated Approval - Nasdaq
ZNTL Pharmaceuticals Updates on Azenosertib Development - GuruFocus
What drives Zentalis Pharmaceuticals Inc stock priceGap Fill Strategies & Double Or Triple Capital - earlytimes.in
Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - MarketScreener
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of “Hold” by Brokerages - Defense World
Will Zentalis Pharmaceuticals Inc. stock outperform growth indexes2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Will Zentalis Pharmaceuticals Inc. stock maintain momentum in 2025Weekly Profit Recap & Free Growth Oriented Trading Recommendations - Bölüm Sonu Canavarı
Will Zentalis Pharmaceuticals Inc. stock see PE expansionWeekly Risk Report & AI Powered Buy/Sell Recommendations - DonanımHaber
Why Zentalis Pharmaceuticals Inc. stock is favored by top institutions2025 Key Highlights & Consistent Income Trade Ideas - Улправда
Zentalis Pharmaceuticals Earnings Notes - Trefis
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell - GlobeNewswire Inc.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Matrix Capital Management Comp Sells 7,500,000 Shares of Stock - Defense World
Insider Selling: Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Sells 7,500,000 Shares of Stock - MarketBeat
Zentalis Pharmaceuticals (ZNTL) director reports 7,500,000 share sale - Stock Titan
[8-K] Zentalis Pharmaceuticals, Inc. Reports Material Event | ZNTL SEC FilingForm 8-K - Stock Titan
Oppenheimer cuts Zentalis stock target to $10, maintains rating - MSN
Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Zentalis Pharma (ZNTL) Stock Analysis Report | Financials & Insights - Benzinga
Can Zentalis Pharmaceuticals Inc. stock surprise with earnings upside2025 Volume Leaders & Reliable Entry Point Alerts - Newser
An analyst sees good growth prospects for Zentalis Pharmaceuticals Inc (ZNTL) - setenews.com
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate - Yahoo Finance
Is Zentalis Pharmaceuticals Inc. stock a safe haven asset2025 Risk Factors & Long-Term Growth Portfolio Plans - Newser
New Highs: Will Zentalis Pharmaceuticals Inc stock outperform growth indexesMarket Risk Report & Risk Controlled Stock Pick Alerts - BỘ NỘI VỤ
Is Zentalis Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Summary & Free Daily Entry Point Trade Alerts - Newser
Are Bears Losing Grip on Artson LimitedMarket Capitalization Trends & Reduce Losses With Smart Exit Strategies - earlytimes.in
Is Zentalis Pharmaceuticals Inc. stock trading near support levels2025 Pullback Review & Long-Term Growth Stock Strategies - BỘ NỘI VỤ
Zentalis Pharmaceuticals Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Perhaps timely catching Zentalis Pharmaceuticals Inc (ZNTL) would be a good idea - Setenews
Connor Clark & Lunn Investment Management Ltd. Decreases Stake in Zentalis Pharmaceuticals, Inc. $ZNTL - Defense World
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
What indicators show strength in Zentalis Pharmaceuticals Inc.Portfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Is Zentalis Pharmaceuticals Inc. stock in correction or buying zoneMarket Volume Summary & Free Verified High Yield Trade Plans - newser.com
Why analysts upgrade Zentalis Pharmaceuticals Inc. stockEarnings Performance Report & Weekly Setup with High ROI Potential - newser.com
Why Zentalis Pharmaceuticals Inc. stock is in analyst buy zone2025 Analyst Calls & AI Driven Stock Reports - newser.com
Is Zentalis Pharmaceuticals Inc. forming a bottoming base2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval (ZNTL) - Seeking Alpha
Multi asset correlation models including Zentalis Pharmaceuticals Inc.Earnings Beat & Weekly High Conviction Trade Ideas - newser.com
How geopolitical tensions affect Zentalis Pharmaceuticals Inc. stockBuy Signal & Momentum Based Trading Ideas - newser.com
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - MarketBeat
Finanzdaten der Zentalis Pharmaceuticals Inc-Aktie (ZNTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Zentalis Pharmaceuticals Inc-Aktie (ZNTL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Myers Scott Dunseth | Director |
Apr 30 '25 |
Buy |
1.40 |
21,000 |
29,373 |
281,192 |
| Bruns Ingmar | Chief Medical Officer |
Feb 06 '25 |
Buy |
2.28 |
20,000 |
45,656 |
36,629 |
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):